Bioinformatics
Integrated bioinformatics, biostatistics and modelling tools that shift experiments from in‑vitro to in‑silico and predict long‑term stability.
Bioinformatics, Biostatistics and Design of Experiment (DoE) are combined at Leukocare to explore a broader design space than conventional approaches to reach optimal formulations in less time at lower costs. In comparison to trial-and-error and high-throughput screening, the rational design of wet-lab experiments together with in silico analyses requires less drug substance and yields more value for each experiment.
Design of Experiments (DoE) instead of high-throughput screening
Pharma 4.0: advanced device digitalization and data processing
Automated data quality checks in accordance with Quality by Design principles
AI to predict drug and formulation properties
Diagram shows an optimization design space
Molecular modelling and structural analysis
Client services for structurally-informed selection of protein drug candidates
Customized algorithms to predict long-term drug stability
Response surface methodology to predict stability of untested formulations
Model shows the prediction of aggregation sites
Response Surface Methodology:
Contours based on RSM intuitively predict the best concentration of excipients' combinations
Synergistic interactions between excipients are detected and exploited for enhancing formulation composition.
Enhanced Drug Substance stability for the development of optimal formulations
Data-driven bioinformatics using innovative methods to save time in drug formulation development.
Picture shows response surface methodology contour plot.
